Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Aug 24;326(8):697-698.
doi: 10.1001/jama.2021.12481.

Two Models of Legalization of Psychedelic Substances: Reasons for Concern

William R Smith  1   2 , Paul S Appelbaum  3   4
Affiliations

Two Models of Legalization of Psychedelic Substances: Reasons for Concern

William R Smith et al. JAMA. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Disclosures: Dr Smith reported receiving support from grant R25M119043 from the National Institute of Mental Health. No other disclosures were reported.

Comment in

References

    1. Reiff CM, Richman EE, Nemeroff CB, et al. Psychedelics and psychedelic-assisted psychotherapy. Am J Psychiatry. 2020;177(5):391–410. - PubMed
    1. Carhart-Harris R, Giribaldi B, Watts R, et al. Trial of psilocybin versus escitalopram for depression. N Engl J Med. 2021;384(15):1402–1411. - PubMed
    1. Mitchell JM, Bogenschutz M, Lilienstein A, et al. MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study. Nat Med. 2021;27(6):1025–1033. - PMC - PubMed
    1. Noseda R, Schmid Y, Scholz I, et al. MDMA-related presentations to the emergency departments of the European Drug Emergencies Network plus (Euro-DEN Plus) over the four-year period 2014–2017. Clin Toxicol (Phila). 2021;59(2): 131–137. - PubMed
    1. Carbonaro TM, Bradstreet MP, Barrett FS, et al. Survey study of challenging experiences after ingesting psilocybin mushrooms. J Psychopharmacol. 2016;30(12):1268–1278. - PMC - PubMed